BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30485824)

  • 1. Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.
    Papp E; Hallberg D; Konecny GE; Bruhm DC; Adleff V; Noë M; Kagiampakis I; Palsgrove D; Conklin D; Kinose Y; White JR; Press MF; Drapkin R; Easwaran H; Baylin SB; Slamon D; Velculescu VE; Scharpf RB
    Cell Rep; 2018 Nov; 25(9):2617-2633. PubMed ID: 30485824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.
    Fang F; Cardenas H; Huang H; Jiang G; Perkins SM; Zhang C; Keer HN; Liu Y; Nephew KP; Matei D
    Cancer Res; 2018 Feb; 78(3):631-644. PubMed ID: 29229600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
    Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
    Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.
    Yang C; Cai J; Wang Q; Tang H; Cao J; Wu L; Wang Z
    Gynecol Oncol; 2012 Feb; 124(2):325-34. PubMed ID: 22005523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.
    Gloss BS; Patterson KI; Barton CA; Gonzalez M; Scurry JP; Hacker NF; Sutherland RL; O'Brien PM; Clark SJ
    Cancer Lett; 2012 May; 318(1):76-85. PubMed ID: 22155104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.
    Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D
    Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells.
    Ahluwalia A; Hurteau JA; Bigsby RM; Nephew KP
    Gynecol Oncol; 2001 Aug; 82(2):299-304. PubMed ID: 11531283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
    Gyparaki MT; Papavassiliou AG
    Clin Breast Cancer; 2018 Jun; 18(3):189-191. PubMed ID: 29042129
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
    Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
    Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.
    Spillman MA; Lacy J; Murphy SK; Whitaker RS; Grace L; Teaberry V; Marks JR; Berchuck A
    Gynecol Oncol; 2007 May; 105(2):312-20. PubMed ID: 17276500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
    Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
    Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.
    Braga Lda C; Silva LM; Ramos AP; Piedade JB; Vidigal PV; Traiman P; da Silva Filho AL
    Biomed Pharmacother; 2014 Feb; 68(1):87-91. PubMed ID: 24412083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant epigenetic regulation of GABRP associates with aggressive phenotype of ovarian cancer.
    Sung HY; Yang SD; Ju W; Ahn JH
    Exp Mol Med; 2017 May; 49(5):e335. PubMed ID: 28524180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of EGFR inhibition in ovarian cancer cell proliferation.
    Bull Phelps SL; Schorge JO; Peyton MJ; Shigematsu H; Xiang LL; Miller DS; Lea JS
    Gynecol Oncol; 2008 Jun; 109(3):411-7. PubMed ID: 18423824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer.
    Wrzeszczynski KO; Varadan V; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
    Methods Mol Biol; 2013; 1049():35-51. PubMed ID: 23913207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.